Philip John (P.J.) Brooks joined the NCATS Office of Rare Diseases Research as a program director in August 2018. Prior to that time, he was in the NCATS Division of Clinical Innovation, where he was the lead program director for the Clinical and Translational Science Awards (CTSA) Program Collaborative Innovation Awards, designed to fund projects that will result in novel and creative approaches to overcoming roadblocks in translational science (PAR-18-244 and PAR-18-245). Brooks represents NCATS on the Trans-NIH Microbiome Working Group and Gene Therapy Working Groups. He is also the Working Group Coordinator for the NIH Common Fund program on Somatic Cell Genome Editing.
Brooks received his Ph.D. in neurobiology from the University of North Carolina at Chapel Hill. After completing a postdoctoral fellowship at the Rockefeller University, Brooks became an investigator in the intramural program of the National Institute on Alcohol Abuse and Alcoholism. He developed an internationally recognized research program focused on two distinct areas: the molecular basis of alcohol-related cancer, and rare neurologic diseases resulting from defective DNA repair, including xeroderma pigmentosum, Cockanye syndrome and Fanconi anemia.
Brooks’ research on rare genetic diseases gave him the opportunity to meet with patients and their families, which had a powerful impact on his view of the importance of translational science in rare diseases. He believes that nucleic acids have clear therapeutic potential for single-gene disorders, as indicated by recent approvals of oligonucleotide therapeutics and gene therapy. However, the ability to deliver these complex molecules to the affected cell types remains the limiting factor in many diseases. Brooks wrote a funding opportunity announcement to support innovative approaches to addressing this problem.
Brooks is interested in accelerating clinical trials in rare diseases by moving beyond “one disease at a time” approaches. Examples include the development of therapeutics that target shared molecular mechanisms underlying multiple rare diseases, and the implementation of platform vector gene therapy trials (see: NCATS Collaborative Rare Disease Platform Vector Gene Therapy Trial).